FtsZ-IN-7

Cat. No.: Molecular Formula: Molecular Weight: Target: Pathway: Storage:	HY-149225 C ₂₆ H ₁₈ BrN ₃ O ₃ 500.34 Bacterial Anti-infection Please store the product under the recommended conditions in the Certificate of Analysis.	HN HN HN HN HN HN HN HN HN HN HN HN HN H
---	---	---

Product Data Sheet

BIOLOGICAL ACT			
Description	FtsZ-IN-7 is a potent FtsZ inhibitor, to promote FtsZ polymerization and inhibit GTPase activity of FtsZ. Thus, FtsZ-IN-7 inhibits bacterial division to lead to death of bacterial cells. FtsZ-IN-7 shows bactericidal activity with no significant tendency to trigger bacterial resistance as well as rapid bactericidal properties. And FtsZ-IN-7 shows low hemolytic activity and cytotoxicity to mammalian cells ^[1] .		
In Vitro	(MIC=0.049 μg/mL), B. s FtsZ-IN-7 (1-4× MIC; 0-2- ATCC43300, with notab FtsZ-IN-7 (4 μg/mL; 10 n FtsZ dose-dependently ¹ FtsZ-IN-7 (12.5 μg/mL; 1	 FtsZ-IN-7 (compound B8) inhibits the tested Gram-positive bacteria including methicillin-resistant S. aureus (MRSA) (MIC=0.049 μg/mL), B. subtilis (MIC=0.024 μg/mL) and S. pneumoniae (MIC=0.049 μg/mL)^[1]. FtsZ-IN-7 (1-4× MIC; 0-24 h) inhibits bacterial grwoth. And FtsZ-IN-7 (4× MIC; 4 h) disturbs the cell surface of MRSA ATCC43300, with notable wrinkling and filamentation on their surfaces^[1]. FtsZ-IN-7 (4 μg/mL; 10 min; 25 🖄) promotes FtsZ polymerization and (0.02-0.64 μg/mL; 30 min) inhibits the GTPase activity of FtsZ dose-dependently^[1]. FtsZ-IN-7 (12.5 μg/mL; 1 h; 37 🖄) revealing the negligible hemolytic activity against human erythrocytes RAW264.7 cells^[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Viability Assay^[1] 	
	Cell Line:	MRSA ATCC43300	
	Concentration:	1 × , 2 × , 4 × MIC; MIC=0.049 μg/mL	
	Incubation Time:	0 h, 0.5 h, 1 h, 1.5 h, 2 h, 4 h, 6 h, 8 h, 12 h, 22 h, and 24 h	
	Result:	Inhibited the growth of bacteria, and more fast compared with Vancomycin (HY-B0671).	

REFERENCES

[1]. Qiu H, et al. Design and synthesis of fascaplysin derivatives as inhibitors of FtsZ with potent antibacterial activity and mechanistic study. Eur J Med Chem. 2023 Jun 5;254:115348.



Caution: Product has not been fully validated for medical applications. For research use only.

 Tel: 609-228-6898
 Fax: 609-228-5909
 E-mail: tech@MedChemExpress.com

 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA